Veterinary Services MarketSize, Share & Industry Analysis, 2026-2034By Animal TypeBy Service TypeBy Delivery ChannelBy Practice OwnershipBy Payment Mode
Full title & scope — all 5 axes with their segments
Veterinary Services Market Size, Share & Industry Analysis, By Animal Type (Companion Animal, Production Animal, Others), By Service Type (Physical health monitoring, Diagnostic tests and imaging, Surgery, Others), By Delivery Channel (Hospitals and Clinics, Commercial Facilities, Outdoors/Ambulatory, Others), By Practice Ownership (Independent Practices, Corporate/Chain-Owned Practices), By Payment Mode (Out-of-Pocket, Insurance-Covered), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The estimate is built upward from the number of veterinary visits and procedures performed each year across companion and production animal caseloads, multiplied by the realized revenue per visit or per head for consultation, diagnostic, surgical and preventive care lines separately. Visit volumes are anchored to animal population counts and clinic density by region, and average revenue per visit is set from disclosed pricing and reimbursement data where it exists. This bottom-up build is then checked against the animal health and diagnostics revenue that companies such as Mars, Incorporated (Mars Veterinary Health — VCA, Banfield, BluePearl, Linnaeus, AniCura), IVC Evidensia, National Veterinary Associates (NVA), CVS Group plc, Thrive Pet Healthcare, PetVet Care Centers, VetPartners (UK), Medivet, AmeriVet Veterinary Partners, Mission Veterinary Partners, Southern Veterinary Partners, Ethos Veterinary Health, Compassion-First Pet Hospitals, MedVet, WellHaven Pet Health, Community Veterinary Partners, VetCor, Destination Pet, Greencross Limited, Rarebreed Veterinary Partners, Veterinary Emergency Group (VEG), Suveto, IDEXX Laboratories, Inc., Antech Diagnostics (Mars, Incorporated), Heska Corporation, Zoetis Reference Labs (Zoetis Inc.), Covetrus, Inc. and Kyoritsu Seiyaku Corporation and Boehringer Ingelheim disclose for their veterinary-facing businesses; where the two diverge, the visit-volume or price-per-visit assumption is revisited instead of the company figures themselves.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Primary research targets practice owners and clinic managers who set visit pricing and service mix, procurement and integration leads at corporate practice groups who can speak to consolidation economics, distributors and wholesalers who move pharmaceuticals and diagnostic consumables into clinics and farms, and veterinary licensing and regulatory contacts who track practitioner supply and registration activity. Sampling weights North America and Europe, where corporate consolidation and pet insurance adoption are furthest along and disclosure is richest, while adding enough coverage in Asia Pacific and Latin America to capture livestock-driven demand that the mature markets do not represent.
Desk research draws on national veterinary licensing board registers for practitioner counts, FAO and national agriculture ministry livestock population statistics, and customs trade data filed under the HS codes covering veterinary pharmaceuticals and vaccines to track cross-border supply. Company filings from publicly listed animal health suppliers, including Mars, Incorporated (Mars Veterinary Health — VCA, Banfield, BluePearl, Linnaeus, AniCura), IVC Evidensia, National Veterinary Associates (NVA), CVS Group plc, Thrive Pet Healthcare, PetVet Care Centers, VetPartners (UK), Medivet, AmeriVet Veterinary Partners, Mission Veterinary Partners, Southern Veterinary Partners, Ethos Veterinary Health, Compassion-First Pet Hospitals, MedVet, WellHaven Pet Health, Community Veterinary Partners, VetCor, Destination Pet, Greencross Limited, Rarebreed Veterinary Partners, Veterinary Emergency Group (VEG), Suveto, IDEXX Laboratories, Inc., Antech Diagnostics (Mars, Incorporated), Heska Corporation, Zoetis Reference Labs (Zoetis Inc.), Covetrus, Inc. and Kyoritsu Seiyaku Corporation and Dechra, provide disclosed segment revenue for cross-checking. Pet insurance association penetration data and national veterinary association benchmark surveys fill in payment-mode and practice-economics detail that trade data alone does not capture.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast carries forward the pet ownership and insurance-adoption curves observed in the historical period, tempering the adoption surge recorded during 2020 and 2021 that will not repeat at the same pace. Corporate consolidation is modeled as a gradual share shift from independent to chain-owned practices, not a fixed annual rate, since acquisition activity varies with financing conditions. Livestock-side demand is tied to production volume growth in the countries covered, not to companion animal trends. The forecast holds only if veterinary licensing capacity expands broadly in line with recent trends and no major disease outbreak forces a step change in demand.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Outputs were back-tested against the 2020-2024 historical growth actually implied by the model, confirming the build reproduces the recorded expansion in visit volume and pricing before being extended into the forecast. Segment-level shifts, particularly the pace of insurance-covered payment and corporate practice ownership, were reviewed against the pattern already visible in the historical years, not assumed to continue unchanged. Sensitivities were tested on the insurance-adoption rate, the corporate consolidation pace, and livestock production growth in the largest production animal markets, since each carries enough uncertainty to move the 2034 total by more than a marginal amount.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is firmest for companion animal care and delivery-channel splits in North America and Europe, where clinic pricing and corporate consolidation activity are disclosed with reasonable regularity. It is weaker for production animal spending in Latin America, the Middle East and Africa, and for payment-mode splits outside markets with mature pet insurance industries, where reporting is thin and often inferred from adjacent livestock or agriculture data. A widespread disease outbreak, a sudden shift in veterinary licensing capacity, or a sharp change in livestock trade policy would be the most likely causes of a material revision to this estimate.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Veterinary Services Market projected to reach?
USD 291.71 Billion by 2034, CAGR 9.35%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 34% of global revenue through 2034.
05Which segment leads the market?
Companion Animal is the largest line by animal type, at 57% of revenue in 2025.
06Who are the key companies profiled?
Mars, Incorporated (Mars Veterinary Health — VCA, Banfield, BluePearl, Linnaeus, AniCura), IVC Evidensia, National Veterinary Associates (NVA), CVS Group plc, Thrive Pet Healthcare, PetVet Care Centers, VetPartners (UK), Medivet, AmeriVet Veterinary Partners, Mission Veterinary Partners, Southern Veterinary Partners, Ethos Veterinary Health, Compassion-First Pet Hospitals, MedVet, WellHaven Pet Health, Community Veterinary Partners, VetCor, Destination Pet, Greencross Limited, Rarebreed Veterinary Partners, Veterinary Emergency Group (VEG), Suveto, IDEXX Laboratories, Inc., Antech Diagnostics (Mars, Incorporated), Heska Corporation, Zoetis Reference Labs (Zoetis Inc.), Covetrus, Inc., Kyoritsu Seiyaku Corporation. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.